Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 2/2013

01-10-2013

Regaining Tolerance to a Self-antigen by the Modified Vaccination Technique

Authors: Arpad Zsigmond Barabas, Chad Douglas Cole, Rene Lafreniere, Donald Mackay Weir

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2013

Login to get access

Abstract

Autoimmune diseases are initiated and maintained by complex immunopathological processes in environmental and genetic factor predisposed patients. In certain autoimmune diseases, the etiologies and pathogenesis of the conditions are quite well understood; yet in others, controversy surrounds as to why and how auto-injurious processes start. Clinical and laboratory examinations reasonably well define the state of progression/remission of an autoimmune disease and allow treatment according to observed findings. However, none of the presently employed treatment options are specific. In fact, they are all nonspecific in their actions and have undesirable side effects. Over the years, experiments carried out in animals have shed light on the complex immunopathological processes which contribute to disease development and progression. At least one experimental autoimmune kidney disease—which we shall describe—helps to understand how pathogenic autoimmune responses can be terminated specifically, without side effects. Since the new vaccination method—that we call modified vaccination technique—was successfully implemented in an experimental autoimmune disease model called slowly progressive Heymann nephritis for the termination of pathogenic immune responses by a target antigen-specific treatment modality, we shall highlight its use in providing insight to physicians and autoimmunologists for its future implementation in human autoimmune diseases.
Literature
1.
go back to reference Feldmann M, Steinman L (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:612–619PubMedCrossRef Feldmann M, Steinman L (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:612–619PubMedCrossRef
2.
go back to reference Arnson Y, Shoenfeld Y, Amital H (2009) Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 42:553–560PubMedCrossRef Arnson Y, Shoenfeld Y, Amital H (2009) Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 42:553–560PubMedCrossRef
3.
go back to reference Dorner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5:433–441PubMedCrossRef Dorner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5:433–441PubMedCrossRef
4.
go back to reference Hogan SL, Muller KE, Jennette JC, Falk RJ (1995) A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25:862–875PubMedCrossRef Hogan SL, Muller KE, Jennette JC, Falk RJ (1995) A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25:862–875PubMedCrossRef
5.
go back to reference Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G (2004) Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 44:385–401PubMed Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G (2004) Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 44:385–401PubMed
6.
go back to reference Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F (2005) CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 4:526–531PubMedCrossRef Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F (2005) CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 4:526–531PubMedCrossRef
7.
go back to reference Townsend MJ, Monroe JG, Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 237:264–283PubMedCrossRef Townsend MJ, Monroe JG, Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 237:264–283PubMedCrossRef
8.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 85:277–285PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 85:277–285PubMedCrossRef
9.
go back to reference Weir DM, Pinckard RN (1967) Failure to induce tolerance to rat tissue antigens. Immunology 13:373–380PubMed Weir DM, Pinckard RN (1967) Failure to induce tolerance to rat tissue antigens. Immunology 13:373–380PubMed
10.
go back to reference Weir DM, Elson CJ (1969) Antitissue antibodies and immunological tolerance to self. Arthritis Rheum 12:254–260PubMedCrossRef Weir DM, Elson CJ (1969) Antitissue antibodies and immunological tolerance to self. Arthritis Rheum 12:254–260PubMedCrossRef
11.
go back to reference Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648–652PubMedCrossRef Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648–652PubMedCrossRef
12.
go back to reference Biesecker G, Noble B, Andres GA, Koffler D (1984) Immunopathogenesis of Heymann’s nephritis. Clin Immunol Immunopathol 33:333–338PubMedCrossRef Biesecker G, Noble B, Andres GA, Koffler D (1984) Immunopathogenesis of Heymann’s nephritis. Clin Immunol Immunopathol 33:333–338PubMedCrossRef
13.
14.
go back to reference Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP (1959) Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med 100:660–664PubMedCrossRef Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP (1959) Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med 100:660–664PubMedCrossRef
15.
go back to reference Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18:1217–1225PubMedCrossRef Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18:1217–1225PubMedCrossRef
16.
go back to reference Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30:409–414PubMedCrossRef Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30:409–414PubMedCrossRef
17.
go back to reference Molina V, Shoenfeld Y (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38:235–245PubMedCrossRef Molina V, Shoenfeld Y (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38:235–245PubMedCrossRef
18.
go back to reference Naito T, Kawamura T, Bannai M et al (2002) Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol 129:397–404PubMedCrossRef Naito T, Kawamura T, Bannai M et al (2002) Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol 129:397–404PubMedCrossRef
19.
20.
go back to reference Edgington TS, Glassock RJ, Dixon FJ (1967) Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science 155:1432–1434PubMedCrossRef Edgington TS, Glassock RJ, Dixon FJ (1967) Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science 155:1432–1434PubMedCrossRef
21.
go back to reference Edgington TS, Glassock RJ, Dixon FJ (1968) Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J Exp Med 127:555–572PubMedCrossRef Edgington TS, Glassock RJ, Dixon FJ (1968) Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J Exp Med 127:555–572PubMedCrossRef
22.
go back to reference Kerjaschki D, Farquhar MG (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 79:5557–5581PubMedCrossRef Kerjaschki D, Farquhar MG (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 79:5557–5581PubMedCrossRef
23.
go back to reference Kerjaschki D, Farquhar MG (1983) Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157:667–686PubMedCrossRef Kerjaschki D, Farquhar MG (1983) Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157:667–686PubMedCrossRef
24.
go back to reference Makker SP, Moorthy B (1981) In situ immune complex formation in isolated perfused kidney using homologous antibody. Lab Invest 44:1–5PubMed Makker SP, Moorthy B (1981) In situ immune complex formation in isolated perfused kidney using homologous antibody. Lab Invest 44:1–5PubMed
25.
go back to reference Makker SP (1993) Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis. J Immunol 151:6500–6508PubMed Makker SP (1993) Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis. J Immunol 151:6500–6508PubMed
26.
go back to reference Mendrick DL, Noble B, Brentjens JR, Andres GA (1980) Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int 18:328–343PubMedCrossRef Mendrick DL, Noble B, Brentjens JR, Andres GA (1980) Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int 18:328–343PubMedCrossRef
27.
go back to reference Neale TJ, Couser WG, Salant DJ, Lowenstein LM, Wilson CB (1982) Specific uptake of Heymann’s nephritic kidney eluate by rat kidney: studies in vivo and in isolated perfused kidneys. Lab Invest 46:450–453PubMed Neale TJ, Couser WG, Salant DJ, Lowenstein LM, Wilson CB (1982) Specific uptake of Heymann’s nephritic kidney eluate by rat kidney: studies in vivo and in isolated perfused kidneys. Lab Invest 46:450–453PubMed
28.
go back to reference Neale TJ, Wilson CB (1982) Glomerular antigens in Heymann’s nephritis: reactivity of eluted and circulating antibody. J Immunol 128:323–330PubMed Neale TJ, Wilson CB (1982) Glomerular antigens in Heymann’s nephritis: reactivity of eluted and circulating antibody. J Immunol 128:323–330PubMed
29.
go back to reference Tsukada Y, Ono K, Maezawa A, Yano S, Naruse T (1994) A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border—studies with a monoclonal antibody against pronase-digested tubular antigen. Clin Exp Immunol 96:303–310PubMedCrossRef Tsukada Y, Ono K, Maezawa A, Yano S, Naruse T (1994) A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border—studies with a monoclonal antibody against pronase-digested tubular antigen. Clin Exp Immunol 96:303–310PubMedCrossRef
30.
go back to reference Barabas AZ, Weir DM, Cole CD et al (2009) Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci 14:3892–3898CrossRef Barabas AZ, Weir DM, Cole CD et al (2009) Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci 14:3892–3898CrossRef
31.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 85:321–334PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 85:321–334PubMedCrossRef
32.
go back to reference Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol 13:17–24PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol 13:17–24PubMedCrossRef
33.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics Targets Ther 1:59–68 Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics Targets Ther 1:59–68
34.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci 1110:619–629PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci 1110:619–629PubMedCrossRef
35.
go back to reference Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2007) A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J 6:12–18 Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2007) A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J 6:12–18
36.
go back to reference Barabas AZ, Cole CD, Graeff RM, Lafreniere R, Weir DM (2011) The role of autoimmunologists in investigating and treating autoimmune disorders. Autoimmun Rev 10:166–170PubMedCrossRef Barabas AZ, Cole CD, Graeff RM, Lafreniere R, Weir DM (2011) The role of autoimmunologists in investigating and treating autoimmune disorders. Autoimmun Rev 10:166–170PubMedCrossRef
37.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) Pathogenic and nonpathogenic autoimmune events—the good and/or the bad? In: Dubois Q (ed) Autoantibodies research progress. Nova Science, Hauppauge, pp 9–18 Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) Pathogenic and nonpathogenic autoimmune events—the good and/or the bad? In: Dubois Q (ed) Autoantibodies research progress. Nova Science, Hauppauge, pp 9–18
38.
go back to reference Weir DM, Pinckard RN, Elson CJ, Suckling DE (1966) Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1:433–442PubMed Weir DM, Pinckard RN, Elson CJ, Suckling DE (1966) Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1:433–442PubMed
39.
go back to reference Batsford SR, Weghaupt R, Takamiya H, Vogt A (1985) Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron 41:146–151PubMedCrossRef Batsford SR, Weghaupt R, Takamiya H, Vogt A (1985) Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron 41:146–151PubMedCrossRef
40.
go back to reference Manson JJ, Mauri C, Ehrenstein MR (2005) Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 26:425–432PubMedCrossRef Manson JJ, Mauri C, Ehrenstein MR (2005) Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 26:425–432PubMedCrossRef
41.
go back to reference Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB (2005) IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 38:259–264PubMedCrossRef Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB (2005) IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 38:259–264PubMedCrossRef
42.
go back to reference Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M (2005) Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 35:252–260PubMedCrossRef Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M (2005) Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 35:252–260PubMedCrossRef
43.
go back to reference Wermeling F, Karlsson MC, McGaha TL (2009) An anatomical view on macrophages in tolerance. Autoimmun Rev 9:49–52PubMedCrossRef Wermeling F, Karlsson MC, McGaha TL (2009) An anatomical view on macrophages in tolerance. Autoimmun Rev 9:49–52PubMedCrossRef
44.
go back to reference Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA (2004) Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity 37:95–102PubMedCrossRef Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA (2004) Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity 37:95–102PubMedCrossRef
45.
go back to reference Orbach H, Shoenfeld Y (2007) Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 6:261–266PubMedCrossRef Orbach H, Shoenfeld Y (2007) Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 6:261–266PubMedCrossRef
46.
47.
go back to reference Schoonen WM, Thomas SL, Somers EC et al (2010) Do selected drugs increase the risk of lupus? A matched case–control study. Br J Clin Pharmacol 70:588–596PubMedCrossRef Schoonen WM, Thomas SL, Somers EC et al (2010) Do selected drugs increase the risk of lupus? A matched case–control study. Br J Clin Pharmacol 70:588–596PubMedCrossRef
48.
go back to reference Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2008) New vaccination technology for endogenous antigen-derived ailments. IDrugs 11:111–115PubMed Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2008) New vaccination technology for endogenous antigen-derived ailments. IDrugs 11:111–115PubMed
49.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2003) Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol 84:245–258PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2003) Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol 84:245–258PubMedCrossRef
50.
go back to reference Challice J, Barabas AZ, Cornish J, Bruce JW, Lannigan R (1986) Passive Heymann nephritis in pre-and post-natal rats. Br J Exp Pathol 67:915–924PubMed Challice J, Barabas AZ, Cornish J, Bruce JW, Lannigan R (1986) Passive Heymann nephritis in pre-and post-natal rats. Br J Exp Pathol 67:915–924PubMed
51.
52.
go back to reference Barabas AZ, Lafreniere R (2005) Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 4:565–570PubMedCrossRef Barabas AZ, Lafreniere R (2005) Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 4:565–570PubMedCrossRef
53.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2006) Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 56:181–190PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2006) Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 56:181–190PubMedCrossRef
54.
go back to reference Barabas AZ, Cole CD, Weir DM, Lafreniere R (2011) Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In: Petrov M (ed) Autoimmune disorders: symptoms, diagnosis and treatment. Nova Science, Hauppauge, pp 35–66 Barabas AZ, Cole CD, Weir DM, Lafreniere R (2011) Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In: Petrov M (ed) Autoimmune disorders: symptoms, diagnosis and treatment. Nova Science, Hauppauge, pp 35–66
55.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) An experimental autoimmune kidney disease caused by pathogenic autoantibodies. In: Petrelli C (ed) New research on autoantibodies. Nova Science, Hauppauge, pp 151–172 Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) An experimental autoimmune kidney disease caused by pathogenic autoantibodies. In: Petrelli C (ed) New research on autoantibodies. Nova Science, Hauppauge, pp 151–172
56.
go back to reference Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int 56:516–529PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int 56:516–529PubMedCrossRef
57.
58.
60.
go back to reference Barabas AZ, Cole CD, Barabas AD, Lafreniere R, Weir DM (2011) Four aspects of autoimmunity and how to regain tolerance to self from an autoimmune disease utilizing the modified vaccination technique. In: Huang FP (ed) Autoimmune disorders—current concepts and advances from bedside to mechanistic insights. InTech, Rijeka, pp 569–590 Barabas AZ, Cole CD, Barabas AD, Lafreniere R, Weir DM (2011) Four aspects of autoimmunity and how to regain tolerance to self from an autoimmune disease utilizing the modified vaccination technique. In: Huang FP (ed) Autoimmune disorders—current concepts and advances from bedside to mechanistic insights. InTech, Rijeka, pp 569–590
61.
go back to reference Kerjaschki D (1993) Molecular development of immune deposits and proteinuria in Heymann nephritis. Clin Investig 71:817–821PubMedCrossRef Kerjaschki D (1993) Molecular development of immune deposits and proteinuria in Heymann nephritis. Clin Investig 71:817–821PubMedCrossRef
62.
go back to reference Barabas AZ, Cole CD, Barabas AD et al (2004) Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 85:201–212PubMedCrossRef Barabas AZ, Cole CD, Barabas AD et al (2004) Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 85:201–212PubMedCrossRef
63.
go back to reference Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S (1986) Formation of immune deposits and disease. Lab Invest 55:510–520PubMed Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S (1986) Formation of immune deposits and disease. Lab Invest 55:510–520PubMed
64.
go back to reference Barabas AZ, Cole CD, Lafreniere R, Weir DM (2011) Prophylactic and therapeutic application of a new vaccination technique for combating autoimmune disorders. In: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Shoenfeld Y (eds) From prediction to prevention of autoimmune diseases—report on the 10th Dresden symposium on autoantibodies held in Dresden on September 22–25, 2011. PABST Science, Berlin, pp 519–539 Barabas AZ, Cole CD, Lafreniere R, Weir DM (2011) Prophylactic and therapeutic application of a new vaccination technique for combating autoimmune disorders. In: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Shoenfeld Y (eds) From prediction to prevention of autoimmune diseases—report on the 10th Dresden symposium on autoantibodies held in Dresden on September 22–25, 2011. PABST Science, Berlin, pp 519–539
65.
go back to reference Kerjaschki D, Neale TJ (1996) Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7:2518–2526PubMed Kerjaschki D, Neale TJ (1996) Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7:2518–2526PubMed
66.
go back to reference Ronco P, Debiec H (2006) Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol 17:1772–1774PubMedCrossRef Ronco P, Debiec H (2006) Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol 17:1772–1774PubMedCrossRef
67.
go back to reference Ronco P, Debiec H (2006) New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 15:258–263PubMedCrossRef Ronco P, Debiec H (2006) New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 15:258–263PubMedCrossRef
68.
go back to reference Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J (2000) Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 97:1184–1189PubMedCrossRef Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J (2000) Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 97:1184–1189PubMedCrossRef
69.
go back to reference Gullstrand B, Martensson U, Sturfelt G, Bengtsson AA, Truedsson L (2009) Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 156:303–311PubMedCrossRef Gullstrand B, Martensson U, Sturfelt G, Bengtsson AA, Truedsson L (2009) Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 156:303–311PubMedCrossRef
70.
go back to reference Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188:2313–2320PubMedCrossRef Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188:2313–2320PubMedCrossRef
71.
go back to reference Pereira WO, Amarante-Mendes GP (2011) Apoptosis: a programme of cell death or cell disposal? Scand J Immunol 73:401–407PubMedCrossRef Pereira WO, Amarante-Mendes GP (2011) Apoptosis: a programme of cell death or cell disposal? Scand J Immunol 73:401–407PubMedCrossRef
72.
go back to reference Pinckard RN, Weir DM (1966) Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol 1:33–43PubMed Pinckard RN, Weir DM (1966) Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol 1:33–43PubMed
73.
go back to reference Noble B, Van Liew JB, Brentjens JR, Andres GA (1982) Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest 47:427–436PubMed Noble B, Van Liew JB, Brentjens JR, Andres GA (1982) Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest 47:427–436PubMed
75.
go back to reference Rao T, Richardson B (1999) Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 107(Suppl 5):737–742PubMedCrossRef Rao T, Richardson B (1999) Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 107(Suppl 5):737–742PubMedCrossRef
77.
go back to reference Ebringer A, Thorpe C, Pirt J, Wilson C, Cunningham P, Ettelaie C (1997) Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens? Environ Health Perspect 105:1172–1174PubMedCrossRef Ebringer A, Thorpe C, Pirt J, Wilson C, Cunningham P, Ettelaie C (1997) Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens? Environ Health Perspect 105:1172–1174PubMedCrossRef
78.
go back to reference Ebringer A (2003) Molecular mimicry as the basis of a new theory of autoimmunity. In: Zouali M (ed) Frontiers in autoimmunity: fundamental aspects and clinical perspectives. Ios, Amsterdam, pp 79–99 Ebringer A (2003) Molecular mimicry as the basis of a new theory of autoimmunity. In: Zouali M (ed) Frontiers in autoimmunity: fundamental aspects and clinical perspectives. Ios, Amsterdam, pp 79–99
79.
go back to reference Ebringer A, Hughes L, Rashid T, Wilson C (2005) Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol 62:33–36PubMedCrossRef Ebringer A, Hughes L, Rashid T, Wilson C (2005) Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol 62:33–36PubMedCrossRef
80.
go back to reference Ebringer A, Rashid T (2009) Rheumatoid arthritis is caused by proteus: the molecular mimicry theory and Karl Popper. Front Biosci (Elite Ed) 1:577–586 Ebringer A, Rashid T (2009) Rheumatoid arthritis is caused by proteus: the molecular mimicry theory and Karl Popper. Front Biosci (Elite Ed) 1:577–586
81.
go back to reference Barabas AZ, Cole CD, Lafreniere R, Weir DM (2012) Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease. Autoimmunity 45:495–509PubMedCrossRef Barabas AZ, Cole CD, Lafreniere R, Weir DM (2012) Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease. Autoimmunity 45:495–509PubMedCrossRef
82.
go back to reference Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM (2010) Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol 71:125–133PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM (2010) Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol 71:125–133PubMedCrossRef
83.
go back to reference Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R (2007) Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit 13:BR119–BR124PubMed Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R (2007) Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit 13:BR119–BR124PubMed
84.
go back to reference Barabas AZ, Cole CD, Sensen M, Lafreniere R (2012) Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol 93:11–17PubMedCrossRef Barabas AZ, Cole CD, Sensen M, Lafreniere R (2012) Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol 93:11–17PubMedCrossRef
85.
go back to reference Avrameas S (1991) Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today 12:154–159PubMed Avrameas S (1991) Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today 12:154–159PubMed
86.
go back to reference Radbruch A, Muehlinghaus G, Luger EO et al (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741–750PubMedCrossRef Radbruch A, Muehlinghaus G, Luger EO et al (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741–750PubMedCrossRef
Metadata
Title
Regaining Tolerance to a Self-antigen by the Modified Vaccination Technique
Authors
Arpad Zsigmond Barabas
Chad Douglas Cole
Rene Lafreniere
Donald Mackay Weir
Publication date
01-10-2013
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2013
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-012-8350-y

Other articles of this Issue 2/2013

Clinical Reviews in Allergy & Immunology 2/2013 Go to the issue